# South Korea Recombinant Vaccines Market > South Korea Recombinant Vaccines Market Research Report: By Product (Subunit Recombinant, Attenuated Recombinant Vaccines), By Disease (Cancer, Pneumococcal Disease, Hepatitis B, DPT) andBy End-Users (Pediatrics, Adults, Veterinary) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 16.57% - **2024:** $ 9 Million - **2025:** $ 10.49 Million - **2035:** $ 48.62 Million - **Key Players:** Pfizer (US), Moderna (US), Novavax (US), Sanofi (FR), GSK (GB), Merck (US), Bavarian Nordic (DK), AstraZeneca (GB), Takeda (JP) **Report ID:** MRFR/Pharma/54240-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-recombinant-vaccines-market-56006 --- ## Market Summary ## **South Korea Recombinant Vaccines Market Overview****:** As per MRFR analysis, the South Korea Recombinant Vaccines Market Size was estimated at 5.8 (USD Million) in 2024.The South Korea Recombinant Vaccines Market Industry is expected to grow from 7.2(USD Million) in 2025 to 96 (USD Million) by 2035. The South Korea Recombinant Vaccines Market CAGR (growth rate) is expected to be around 26.551% during the forecast period (2025 - 2035). ### **Key South Korea Recombinant Vaccines Market Trends Highlighted** The South Korea recombinant vaccines market is experiencing significant growth driven by various factors. One of the key market drivers is the increasing focus of the South Korean government on public health and vaccination programs. The nation has been actively investing in vaccine research and development, aiming to enhance its capability to respond to infectious diseases.  This shift is further supported by collaborations between government, academic institutions, and private firms, leading to the emergence of innovative vaccine technologies. Additionally, the rising prevalence of infectious diseases, paired with growing awareness among the public about the importance of vaccinations, propels the demand for recombinant vaccines.Opportunities to be explored in this market are abundant, particularly in the realm of personalized medicine and innovative delivery systems.  South Korea has a robust biotechnology sector, which paves the way for the development of next-generation vaccines that are tailored to specific populations and disease profiles. Moreover, the increasing acceptance of recombinant vaccines in veterinary medicine offers additional market potential. The government’s regulatory initiatives are also a catalyst, streamlining approval processes for new vaccines, which encourages investments and expedites the introduction of new products into the market. Recent trends indicate a stronger emphasis on collaborative research and public-private partnerships in South Korea's vaccine space. These collaborations have become crucial in the wake of global health emergencies, showcasing the need for rapid development and distribution of vaccines. Furthermore, the country's advancement in genomic research and biotechnology capabilities is enabling the production of more effective recombinant vaccines. With ongoing investments in healthcare technology and innovation, the South Korean recombinant vaccines market is poised for dynamic growth, driven by its focus on modern healthcare solutions and preventive measures. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South Korea Recombinant Vaccines Market Drivers** ### **Increasing Investment in Research and Development** The South Korea [Recombinant Vaccines Market](../../../reports/recombinant-vaccines-market-6130) Industry is experiencing significant growth due to increased investment in Research and Development. The Korean government has demonstrated strong commitment to enhancing healthcare by allocating substantial funds towards biotechnology innovation, with a reported increase of 16% in overall healthcare R&D spending over the last three years.  This focus has been supported by entities like the Korea Health Industry Development Institute, which aims to improve vaccine production capabilities and speed up the development of recombinant vaccines.Such investments are pivotal as South Korea races to enhance its pandemic preparedness and improve overall public health outcomes, especially amidst challenges posed by emerging infectious diseases. The country’s strategic goal is to increase its vaccine production capacity by 50% by 2025, thereby further propelling the South Korea Recombinant Vaccines Market Industry forward. ### **Growing Prevalence of Infectious Diseases** The rising incidence of infectious diseases in South Korea is a significant driver for the South Korea Recombinant Vaccines Market Industry. The Korea Centers for Disease Control and Prevention reported a 20% increase in outbreaks of vaccine-preventable diseases over the last five years, prompting urgent actions to develop effective immunization solutions. This increase has stimulated collaboration between private vaccine manufacturers and public health authorities to accelerate the development and deployment of recombinant vaccines.Also, well-known initiatives such as the National Immunization Program have been instrumental in growing public awareness about vaccines, and this has been helpful in the recombinant vaccines market as well. ### **Supportive Regulatory Framework** A proactive regulatory environment in South Korea is significantly influencing the growth of the South Korea Recombinant Vaccines Market Industry. The Ministry of Food and Drug Safety is known for its expedited review processes and support programs for vaccine developers, which aim to increase the speed of vaccine approval without compromising safety. Recent regulatory modifications have resulted in a 30% reduction in approval time for novel vaccines, fostering confidence among investors and enhancing collaborations between private enterprises and public institutions.Such a conducive regulatory landscape is essential for fostering innovation, ultimately stimulating market growth. ### **Rising Health Awareness and Public Support** Growing health awareness among the South Korean population is greatly contributing to the expansion of the South Korea Recombinant Vaccines Market Industry. Surveys conducted by the Ministry of Health and Welfare indicate a 40% increase in the public's understanding the importance of vaccination over the last decade. Educational campaigns and health initiatives have driven this awareness, leading to greater acceptance of recombinant vaccines.As citizens become more informed about their benefits, demand for these vaccines is projected to increase, further promising an upward trajectory for the market. ## **South Korea Recombinant Vaccines Market Segment Insights****:** ### **Recombinant Vaccines Market Product Insights** The South Korea Recombinant Vaccines Market, particularly within the Product segment, has demonstrated significant growth potential driven by advancements in biotechnology and increased awareness of preventive healthcare measures. Recombinant vaccines are distinguished by their effectiveness, safety profiles, and specificity, which contribute to their growing acceptance in various immunization programs.  Among the key types within this segment, Subunit Recombinant vaccines stand out due to their capability to induce strong immune responses without the risk of causing disease, making them particularly suited for complex pathogens.This sub-type typically utilizes purified proteins from the pathogen, enhancing safety and efficacy, thus appealing to a broad spectrum of healthcare providers and patients alike.  On the other hand, Attenuated Recombinant Vaccines play an essential role in stimulating both humoral and cellular immunity, offering a more holistic approach to vaccination. Their unique formulation allows for a robust immune response, which can provide long-lasting protection. With South Korea's robust healthcare infrastructure and commitment to innovation in medical research, there remains a favorable environment for the continued development and adoption of these vaccine types. The government’s initiatives to enhance pandemic preparedness and strengthen public health systems contribute significantly to the growth of the South Korea Recombinant Vaccines Market, as they foster Research and Development aimed at improving vaccine technology. The increasing incidence of infectious diseases and the need for effective vaccination strategies provide ample opportunities for market players to innovate their offerings.  In this dynamic landscape, the emphasis on both Subunit and Attenuated Recombinant vaccines ensures that the South Korean market remains at the forefront of vaccine development, catering to the evolving challenges posed by global health threats.The burgeoning interest in biotechnology, supported by substantial government and private sector investment, creates a strong foundation for these products, indicating a promising trajectory for the market in the coming years. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Recombinant Vaccines Market Disease Insights** The South Korea Recombinant Vaccines Market, particularly in the Disease segment, exhibits a robust growth trajectory, largely driven by increasing incidences of various ailments and an emphasis on preventive healthcare. Cancer vaccines have gained significant attention due to rising cancer rates in the region, highlighting the crucial need for innovative immunization solutions that can provide protection against this growing threat. Similarly, vaccines targeting Pneumococcal Disease are vital to reducing morbidity and mortality associated with respiratory infections, especially among vulnerable populations. Hepatitis B vaccines also hold significant importance, contributing to national efforts aimed at eradicating this virus, which poses a significant public health challenge. Additionally, the combined Diphtheria, Pertussis, and Tetanus (DPT) vaccines contribute to comprehensive immunization programs, ensuring widespread protection and safeguarding public health. With the South Korean government's commitment to advancing vaccine development and distribution, these categories within the South Korea Recombinant Vaccines Market are poised for significant advancements, addressing the nation's healthcare priorities.The continuous evolution of biotechnology is expected to further enhance the efficacy and delivery of these vaccines, fostering a healthier population while contributing to the overall market growth. ### **Recombinant Vaccines Market End-User Insights** The End-Users segment of the South Korea Recombinant Vaccines Market reflects diverse applications across various demographics. This segment is primarily divided into three main categories: Pediatrics, Adults, and Veterinary. The Pediatrics category is significant as it addresses the healthcare needs of infants and young children, ensuring they receive protection against preventable diseases at a crucial stage of development.  The Adult population also plays a vital role, with an increasing emphasis on preventive healthcare driven by rising awareness regarding vaccination and public health initiatives in South Korea.Furthermore, the Veterinary sector underscores the importance of vaccines in animal health, contributing to food safety and preventing zoonotic diseases, which is particularly relevant given South Korea’s advancing agricultural practices.  The growing interest in personalized medicine and biotechnology is driving the innovation of recombinant vaccines across these demographics, promising more effective treatments and new market opportunities. Collectively, these segments represent a comprehensive approach to public health in South Korea, poised for growth as investment in Research and Development continues and awareness ramps up among the population.The South Korea Recombinant Vaccines Market statistics suggest a strong future as healthcare systems evolve to meet the needs of both humans and animals through innovative vaccine solutions. ## **South Korea Recombinant Vaccines Market Key Players and Competitive Insights****:** The South Korea Recombinant Vaccines Market has seen significant evolution, characterized by increasing competition among key players that are striving to enhance their market presence. This market is driven by advancements in biotechnology and the rising incidence of infectious diseases, which have heightened the demand for effective vaccination solutions. Companies in this sector are focusing on innovation, product development, and strategic collaborations to capitalize on emerging opportunities.  The growing awareness among the population regarding vaccine importance and the support from the South Korean government for vaccine research and development are additional factors contributing to the competitive dynamics. The market is not only becoming increasingly crowded but also showcases varied product offerings that aim to meet the specific health needs of the population.Pfizer has established itself as a formidable player in the South Korea Recombinant Vaccines Market, benefiting from its strong global brand recognition and extensive research capabilities.  The company’s commitment to developing innovative vaccines positions it well within the localized market environment. Pfizer's strengths lie in its robust pipeline of recombinant vaccines and the company's history of effective public health initiatives. Its established relationships with healthcare professionals and public health organizations in South Korea provide an advantage in dissemination and educational efforts about its vaccine offerings. Furthermore, Pfizer's significant investments in marketing and collaborations with local entities facilitate a better understanding of market needs and customer preferences, further enhancing its competitive stance. GC Pharma has emerged as a notable player within the South Korea Recombinant Vaccines Market, focusing on producing high-quality vaccines and biologics. The company holds a diverse portfolio of key products that include recombinant vaccines aimed at preventing infectious diseases prevalent in the region. GC Pharma's strong market presence is bolstered by its commitment to research and development, which has led to successful collaborations and partnerships aimed at advancing vaccine technology.  The company’s strengths include its expertise in biopharmaceutical manufacturing and a solid distribution network that ensures efficient delivery of its products. GC Pharma has also engaged in strategic mergers and acquisitions, which have amplified its capacity to compete aggressively and innovate within this evolving market landscape in South Korea, providing tailored solutions that align with local health priorities. ### **Key Companies in the South Korea Recombinant Vaccines Market Include:** - Pfizer - GC Pharma - SK Bioscience - Korea Vaccine - Moderna - Novavax - Seegene - Merck & Co. - Sanofi - LG Chem - Daewoong Pharmaceutical - Hanmi Pharm - Janssen Biologics - GSK - Samsung Biologics ## **South Korea Recombinant Vaccines Market Industry Developments** The South Korea Recombinant Vaccines Market is witnessing significant developments, particularly with the ongoing efforts of companies like Pfizer and Moderna in vaccine innovations. In November 2023, SK Bioscience reported a strategic partnership with Novavax to enhance their vaccine production capabilities in response to varying health threats. Meanwhile, GC Pharma has focused on expanding its recombinant vaccine pipeline, which aligns with the government's initiative to boost domestic vaccine production, evidenced by the establishment of the Korea Vaccine National Center. Recent growth in the market valuation of companies like Samsung Biologics highlights a strong commitment to Research and Development in the recombinant vaccine sector.  Over the past few years, notable events include Merck and Co.'s investment in local biotech firms to accelerate vaccine development as of May 2022, which has contributed to enhancing the nation's vaccination capacity. Furthermore, Hanmi Pharm has emerged as a key player, impacting the market with innovative solutions. Continuous advancements in recombinant technology by these companies are expected to further bolster South Korea's position in the global vaccine market, ensuring a robust response to public health challenges. ## **South Korea Recombinant Vaccines Market Segmentation Insights** ### **Recombinant Vaccines Market Product****Outlook** - Subunit Recombinant - Attenuated Recombinant Vaccines ### **Recombinant Vaccines Market Disease****Outlook** - Cancer - Pneumococcal Disease - Hepatitis B - DPT ### **Recombinant Vaccines Market End-Users****Outlook** - Pediatrics - Adults - Veterinary ## Market Drivers ### Rising Incidence of Infectious Diseases The rising incidence of infectious diseases in South Korea is a significant driver for the recombinant vaccines market. Recent data indicates that the prevalence of vaccine-preventable diseases has increased, prompting public health authorities to seek effective vaccination solutions. The recombinant vaccines market is particularly well-positioned to address these challenges, as these vaccines can be tailored to target specific pathogens. For example, the emergence of new strains of influenza has led to increased demand for vaccines that can provide broader protection. This trend suggests that the recombinant vaccines market will continue to grow as healthcare providers and policymakers prioritize vaccination as a key strategy in disease prevention. ### Growing Demand for Personalized Medicine The growing demand for personalized medicine is influencing the recombinant vaccines market in South Korea. As healthcare shifts towards more individualized treatment approaches, there is an increasing interest in vaccines that can be tailored to specific patient profiles. This trend is particularly relevant in the context of genetic predispositions to certain diseases. The recombinant vaccines market is well-suited to meet this demand, as these vaccines can be designed to target specific antigens based on individual genetic information. This potential for customization may drive further investment and research in the sector, ultimately leading to a more robust market presence. ### Government Support and Funding Initiatives Government support plays a crucial role in the growth of the recombinant vaccines market in South Korea. The government has implemented various funding initiatives aimed at bolstering vaccine research and development. In recent years, funding has increased significantly, with allocations reaching over $150 million annually for vaccine-related projects. This financial backing not only encourages private sector investment but also fosters collaboration between academic institutions and biotech companies. Such partnerships are essential for accelerating the development of innovative vaccines. Consequently, the recombinant vaccines market is poised for growth, as government support enhances the overall research ecosystem. ### Technological Advancements in Vaccine Development The recombinant vaccines market in South Korea is experiencing a surge due to rapid technological advancements in vaccine development. Innovations in genetic engineering and biotechnology are enabling the creation of more effective and safer vaccines. For instance, the use of recombinant DNA technology allows for the production of vaccines that can elicit stronger immune responses. This is particularly relevant in the context of emerging infectious diseases, where traditional vaccine methods may fall short. The South Korean government has recognized the potential of these technologies, allocating approximately $200 million to support research initiatives in this area. As a result, the recombinant vaccines market is likely to expand, driven by the increasing availability of advanced vaccine candidates. ### Increased Collaboration Between Public and Private Sectors Collaboration between public and private sectors is becoming increasingly vital for the recombinant vaccines market in South Korea. This synergy facilitates the sharing of resources, expertise, and technology, which can significantly enhance vaccine development processes. Public institutions often provide foundational research, while private companies contribute advanced manufacturing capabilities. Recent partnerships have led to the successful development of several recombinant vaccines, demonstrating the effectiveness of this collaborative approach. As these partnerships continue to evolve, the recombinant vaccines market is likely to benefit from accelerated innovation and improved access to vaccines for the population. ## Future Outlook The [Recombinant Vaccines Market](https://www.marketresearchfuture.com/reports/recombinant-vaccines-market-6130) is projected to grow at a 16.57% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare investments. **New opportunities:** - Development of personalized vaccine platforms for niche markets. - Expansion of partnerships with biotech firms for innovative product pipelines. - Investment in cold chain logistics to enhance distribution efficiency. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in vaccine innovation. ## Segment Insights ### By Type: Subunit (Largest) vs. Vector (Fastest-Growing) In the South Korea recombinant vaccines market, subunit recombinant vaccines hold the largest share, predominantly due to their established safety profile and effectiveness against various diseases. This segment benefits from advancements in biotechnology, which enable the production of highly specific subunit antigens, thereby enhancing immunogenicity. Conversely, vector recombinant vaccines, while currently smaller in market share, are emerging rapidly, spurred by increased investment and research in viral vector technology that enhances vaccine efficacy and delivery systems. The growth trends within the recombinant vaccines market are heavily influenced by the rising incidence of infectious diseases and the ongoing demand for innovative vaccine solutions. Regulatory support and public health initiatives further drive the adoption of vector recombinant vaccines, which are increasingly recognized for their potential in rapid response frameworks against epidemics and pandemics. This combination of market dynamics positions vector vaccines as a significant focus area moving forward. Subunit (Dominant) vs. Vector (Emerging) Subunit recombinant vaccines are notable for their robust safety and efficacy, making them the dominant choice in preventative healthcare within the market. These vaccines leverage pure antigens derived from pathogens, minimizing adverse reactions, which appeals to healthcare providers and patients alike. On the other hand, vector recombinant vaccines are gaining traction as an emerging technology due to their unique mechanisms, using engineered viruses to deliver vaccine components effectively. This characteristic enables them to elicit strong immune responses with potentially fewer doses. As research continues to highlight their capabilities, vector vaccines are poised to capture a larger share of the market as they offer novel solutions to combat emerging infectious threats. ### By Disease: Pneumococcal Disease (Largest) vs. Cancer (Fastest-Growing) In the South Korea recombinant vaccines market, the distribution of market share among various disease segments is a critical element. Pneumococcal disease vaccines currently hold the largest share, driven by high vaccination rates and public health initiatives focusing on infant and elderly populations. Other segments like hepatitis B and influenza also contribute to the market, but they do so to a lesser extent. This market landscape highlights a concentrated focus on the most prevalent diseases, simplifying vaccine development processes and public health strategies. Growth trends in the South Korea recombinant vaccines market are predominantly influenced by increasing healthcare awareness and advancements in biotechnology. Cancer vaccines are noted as the fastest-growing segment, supported by significant investments in research and development. Additionally, evolving government policies advocating vaccination also bolster the growth of various disease segments, enhancing accessibility and driving demand across the board. Pneumococcal Disease (Dominant) vs. Cancer (Emerging) Pneumococcal disease vaccines remain the dominant force in the market, credited for their robust effectiveness against a common yet serious bacterial infection. Made mandatory in many immunization schedules, these vaccines have solidified their place within public health programs. Conversely, cancer vaccines are emerging rapidly, capturing attention due to rising cancer incidence and increased public health initiatives. This segment is characterized by cutting-edge research and potential for customized medicine. As healthcare systems evolve, the importance of both segments will likely increase, with pneumonia vaccines stabilizing the foundation of infectious disease prevention and cancer vaccines ushering in innovative treatment avenues. ### By End-User: Hospitals & Clinics (Largest) vs. Poultry (Fastest-Growing) In the South Korea recombinant vaccines market, the distribution of market share among the end-user segments reveals that Hospitals & Clinics hold the largest share due to their vital role in administering vaccines to both pediatric and adult populations. Following them, the veterinary segment also plays a significant role, but its share is comparatively lower, impacting the overall distribution. Meanwhile, the poultry segment has witnessed an upward trend in adoption, highlighting its growing importance in the overall market dynamics. Growth trends in this segment are being driven predominantly by the increasing demand for vaccine solutions that cater to diverse populations, including pediatrics and adults. Additionally, the rising awareness around animal health, primarily in the veterinary domain, is fostering innovations in recombinant vaccines, particularly for poultry. This reflects the changing landscape, where a segment previously seen as minor is rapidly becoming a crucial player in the market landscape. Hospitals & Clinics (Dominant) vs. Poultry (Emerging) Hospitals & Clinics are the dominant segment in administering recombinant vaccines, leveraging their established infrastructure and trust from patients. They represent the backbone of vaccination efforts, particularly for pediatric and adult demographics, ensuring a steady demand for innovative vaccine solutions. Conversely, the poultry segment, once a secondary market player, is rapidly emerging due to the growing emphasis on biosecurity and disease prevention in livestock. This segment is not only expanding its reach but also increasing investments in vaccine technology, making it a pivotal part of the equation as the focus on animal health intensifies. ## Competitive Benchmarking The recombinant vaccines market in South Korea is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on regional expansion. Major players such as Pfizer (US), Moderna (US), and Novavax (US) are at the forefront, leveraging their advanced research capabilities and established market presence. Pfizer (US) has positioned itself as a leader through continuous investment in R&D, while Moderna (US) emphasizes its mRNA technology platform to develop next-generation vaccines. Novavax (US), on the other hand, is focusing on its protein-based vaccine candidates, which may appeal to specific market segments. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological advancement and collaboration.Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The competitive structure appears moderately fragmented, with several key players vying for market share. This fragmentation allows for a diverse range of products and innovations, although the influence of major companies remains substantial, shaping market trends and consumer preferences. In October Moderna (US) announced a strategic partnership with a South Korean biotech firm to enhance its local manufacturing capabilities. This move is likely to bolster Moderna's supply chain resilience and enable quicker responses to regional demands. By localizing production, the company may also reduce costs and improve its competitive positioning in the South Korean market. In September Novavax (US) received regulatory approval for its latest recombinant vaccine targeting a specific viral strain prevalent in the region. This approval not only signifies a critical milestone for Novavax (US) but also enhances its credibility and market presence in South Korea. The ability to address localized health concerns could potentially lead to increased market penetration and consumer trust. In August Pfizer (US) expanded its collaboration with local health authorities to conduct extensive vaccination campaigns, focusing on public health education and accessibility. This initiative underscores Pfizer's commitment to community engagement and may enhance its brand loyalty among South Korean consumers. Such strategic actions are indicative of a broader trend where companies are not only competing on product efficacy but also on their social responsibility and community impact. As of November current trends in the recombinant vaccines market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and enhancing innovation. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to respond swiftly to emerging health challenges. ## Recent News & Developments The South Korea Recombinant Vaccines Market is witnessing significant developments, particularly with the ongoing efforts of companies like Pfizer and Moderna in vaccine innovations. In November 2023, SK Bioscience reported a strategic partnership with Novavax to enhance their vaccine production capabilities in response to varying health threats. Meanwhile, GC Pharma has focused on expanding its recombinant vaccine pipeline, which aligns with the government's initiative to boost domestic vaccine production, evidenced by the establishment of the Korea Vaccine National Center. Recent growth in the market valuation of companies like Samsung Biologics highlights a strong commitment to Research and Development in the recombinant vaccine sector.  Over the past few years, notable events include Merck and Co.'s investment in local biotech firms to accelerate vaccine development as of May 2022, which has contributed to enhancing the nation's vaccination capacity. Furthermore, Hanmi Pharm has emerged as a key player, impacting the market with innovative solutions. Continuous advancements in recombinant technology by these companies are expected to further bolster South Korea's position in the global vaccine market, ensuring a robust response to public health challenges. ## Report Scope | MARKET SIZE 2024 | 9.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 10.49(USD Million) | | MARKET SIZE 2035 | 48.62(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 16.57% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer (US), Moderna (US), Novavax (US), Sanofi (FR), GSK (GB), Merck (US), Bavarian Nordic (DK), AstraZeneca (GB), Takeda (JP) | | Segments Covered | Type, Disease, End-User | | Key Market Opportunities | Advancements in genetic engineering enhance efficacy and safety in the recombinant vaccines market. | | Key Market Dynamics | Rising demand for innovative recombinant vaccines driven by regulatory support and technological advancements in South Korea. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current valuation of the recombinant vaccines market in South Korea?** A: The market valuation was $9.0 Million in 2024. **Q: What is the projected market size for recombinant vaccines in South Korea by 2035?** A: The projected valuation for 2035 is $48.62 Million. **Q: What is the expected CAGR for the South Korea recombinant vaccines market during 2025 - 2035?** A: The expected CAGR is 16.57% during the forecast period. **Q: Which companies are the key players in the South Korea recombinant vaccines market?** A: Key players include Pfizer, Moderna, Novavax, Sanofi, GSK, Merck, Bavarian Nordic, AstraZeneca, and Takeda. **Q: What are the main types of recombinant vaccines available in South Korea?** A: The main types include subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines. **Q: How did the subunit recombinant vaccines perform in terms of market valuation?** A: The subunit recombinant vaccines had a valuation of $2.7 Million in 2024 and are projected to reach $13.5 Million by 2035. **Q: What diseases are targeted by recombinant vaccines in South Korea?** A: Recombinant vaccines target diseases such as pneumococcal disease, cancer, hepatitis B, influenza, and DPT. **Q: What is the market valuation for cancer-related recombinant vaccines?** A: Cancer-related recombinant vaccines had a valuation of $2.0 Million in 2024 and are expected to grow to $10.0 Million by 2035. **Q: Which end-users are driving the demand for recombinant vaccines in South Korea?** A: End-users include hospitals & clinics, pediatrics, adults, veterinary, poultry, and livestock sectors. **Q: What is the projected market size for recombinant vaccines in hospitals and clinics by 2035?** A: The market size for hospitals & clinics is projected to grow from $1.8 Million in 2024 to $9.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-recombinant-vaccines-market-56006*